Korean J Hematol.  2012 Dec;47(4):241-242. 10.5045/kjh.2012.47.4.241.

Will JAK1/2 inhibitors change the standard of care for myelofibrosis?

• Jung CW

• KMID: 1832099
• DOI: http://doi.org/10.5045/kjh.2012.47.4.241

Abstract

No abstract available.

MeSH Terms

Standard of Care

Reference

1. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012. 366:799–807.

2. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012. 366:787–798.

3. Verstovsek S, Kantarjian HM, Estrov Z, et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. 2012. 120:1202–1209.

4. Tefferi A, Litzow MR, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med. 2011. 365:1455–1457.

5. Scott BL, Gooley TA, Sorror ML, et al. The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. Blood. 2012. 119:2657–2664.